1- Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risque for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–46.
2- Heeringa J, van der Kuip DA, et al. Prevalence, incidence and lifetime risque of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949–53.
3- Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–429.
4- Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 2004; 25: 1734–40.
5- Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84–91.
6- Camm AJ, Lip GY, De Caterina R2012 focused update of the ESC Guidelines for the management of Developed with the special contribution atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24.
7- Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risque of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093–100.
8- Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risque score for predicting bleeding risque in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile RIN, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173–80.
9- The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–12
10- AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–33.
11- Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834–40.
12- Carlsson J, Miketic S, Windeler J, et al, and the STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1690–96.
13- Opolski G, Torbicki A, Kosior DA, et al. Rate control vs. rhythm control in patients with non-valvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 2004; 126: 476–86.
14- Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242–48.
15- Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667–77.
16- Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363–73.
17- Afssaps. Les nouveaux anticoagulants oraux (dabigatran et rivaroxaban) dans la fibrillation auriculaire : ce qu’il faut savoir - Point d'Information. 26/04/2012.
Mise au point
Le suivi des patients immunodéprimés en soins primaires
Etude et pratique
Mesure de la PA, la position du patient est importante
Cas clinique
Le papillome intracanalaire
Recommandations
Prise en charge des pneumonies aiguës communautaires